Celenid is commonly used to help manage symptoms related to systemic imbalance, particularly those involving the inner ear's balance system.

Managing Symptoms of Balance and Motion Disorders

Celenid is applied in clinical settings that involve acute or unstable symptom patterns, such as those caused by labyrinthine disorders and the manifestations of Ménière's disease. The medication is relevant for easing symptoms of rotational vertigo and chronic dizziness, as well as providing supportive management against motion sickness (kinetosis). It is commonly used to help with symptoms that interfere with daily functioning, including the associated symptom clusters of nausea and vomiting, and certain forms of tinnitus.

The primary benefit Celenid provides is symptomatic support for the patient during difficult episodes by easing distress.

This support helps maintain a sense of stability when symptoms are more noticeable, providing supportive relief when symptoms interfere with routine activities. It is applied in situations where short-term symptomatic assistance is needed, in contexts involving temporary physiological imbalance or where a condition produces significant symptomatic burden.

---

Quick Fact: Support for Balance Dysfunction Symptoms Celenid is commonly used to help manage symptoms of balance dysfunction, including moderate to extreme episodes of vertigo and associated nausea, especially in contexts involving chronic inner ear conditions or motion sensitivity.

Eligibility Map: Who can and cannot use [Celenid] — official regulatory information

Eligibility Scope	Official Regulatory Statement
Populations for whom use is allowed	Adults (18 years and older) are the population for whom use is primarily established.
Populations for whom use is not recommended	Children and adolescents under 18 years, as safety and efficacy have not been established.
Populations for whom use is contraindicated	Individuals with hypersensitivity to the active substances or excipients.
Age-related eligibility rules	Not for use in individuals under 18 years of age. Dosage is generally the same for the elderly (65+).
Condition-specific eligibility rules	Contraindicated in severe hepatic impairment and severe renal impairment (creatinine clearance le 25 mL/min).
Pregnancy and lactation eligibility status	Not recommended during pregnancy. Should not be used during breastfeeding.
Eligibility-related restrictions	Must not be used in patients with angle-closure glaucoma, convulsions, suspicion of raised intracranial pressure, alcohol abuse, or urine retention due to urethroprostatic disorders.

---

Official Eligibility Summary

Official regulatory documents classify use in specific groups as contraindicated, establishing absolute exclusions based on conditions like severe organ dysfunction (hepatic or renal) and hypersensitivity to the drug components. The medicine is also strictly excluded in patients with pre-existing conditions sensitive to anticholinergic effects, such as angle-closure glaucoma and urine retention. Use in children, pregnant women, and breastfeeding mothers is either not recommended or contraindicated due to the lack of established safety and efficacy data.

Celenid is a brand name for the active substance Cinnarizine, an antihistamine and calcium channel blocker used to address symptoms of balance disorders and motion sickness. Its interaction profile is largely governed by its antihistaminic properties and its metabolism by liver enzymes.

Potential Drug-Drug Interactions

Interacting Product Category	Interaction Mechanism and Effect	Relevance Classification
Central Nervous System (CNS) Depressants (e.g., alcohol, sedatives, tranquilizers, hypnotics)	Cinnarizine's sedative effect is additive, increasing the risk of enhanced drowsiness, lethargy, or impaired concentration.	Use with Caution/Avoid
Anticholinergic Drugs (e.g., certain antidepressants, antispasmodics)	Cinnarizine possesses anticholinergic properties, and concurrent use with other agents of this class may potentiate side effects such as dry mouth, blurred vision, and urinary retention.	Use with Caution
Anticoagulants (e.g., Warfarin)	Interactions are documented where the metabolism of certain anticoagulants may be decreased, potentially leading to an increased risk of bleeding.	Monitor/Adjust Dose

Cinnarizine is metabolized by the cytochrome P450 (CYP) enzyme system, specifically CYP2D6. Co-administration with strong inhibitors or inducers of this enzyme may lead to altered concentrations of Cinnarizine or the interacting medicine, potentially affecting efficacy or safety. Patients are advised against consuming alcohol while taking this medication due to the heightened risk of sedation.

How Celenid Works at the Biological Level

Modulating Signal Transduction Through Enzyme Inhibition

Celenid is an agent that acts by modulating specific cell signaling cascades, primarily by targeting specific enzyme systems. The molecule functions as a competitive inhibitor of Receptor Tyrosine Kinases (RTKs), a family of regulatory enzymes essential for sending proliferative and anti-apoptotic signaling within cells. By binding to the active site, Celenid physically prevents the enzyme from performing the crucial chemical reaction of phosphorylation, thereby reducing the output of downstream cellular signaling.

Interruption of Growth and Survival Pathways (MAPK/PI3K)

This mechanism directly influences the complex internal signaling known as the MAPK and PI3K pathways, which are critical communication lines for proliferation and resistance to external stress. By interrupting these cascades at their source, Celenid blocks the continuous activation of multiple downstream mediators, such as Akt and mTOR. This alteration of pathway activity influences the activity of pathways that rely on these systems for their function.

Influencing Cellular Homeostasis and Regulated Cell Fate

The collective effect of inhibiting these major pro-survival pathways is an alteration in the ratio of pro-survival to pro-apoptotic factors within the cell. This mechanism engages processes that influence feedback regulation, influencing the resulting equilibrium within targeted systems. The resulting physiological consequence is the promotion of apoptosis (programmed cell death) and the suppression of rapid cell division, determining the physiological consequences of the mechanism.

How to Use Celenid

This section outlines the administration instructions for Celenid, detailing the procedural steps and dosing rules.

Administration Guidelines

Scope	Requirement
Route of Administration	The medicine is taken orally (by mouth).
Timing in Relation to Meals	Doses should be taken after a meal to help minimize potential stomach upset.
Preparation Requirements	Tablets may be swallowed whole with water, chewed, or sucked, as required by the patient.

Dosing and Frequency Rules

The required dose and frequency depend on the specific use context. Schedules are defined for both regular and intermittent use.

For regular use (e.g., balance issues), the standard dosage is typically one or two tablets, three times a day.

For intermittent use (e.g., travel prophylaxis), the first dose must be taken 2 hours before the start of the journey. Subsequent doses are then administered every 8 hours during the period of use.

Age-Specific Administration

Dosing is adjusted based on age:

• Adults and Children over 12 years old: The standard adult dose applies for both regular and intermittent schedules.
• Children aged 5–12 years old: Reduced doses apply, typically half the adult dose.
• Children under 5 years old: Use of this medicine is generally not recommended or is contraindicated.

Procedural Structure

A structured protocol is established for use: first, the appropriate dose is identified based on age and use context. Second, for prophylactic use, the initial administration occurs at a set time (2 hours) prior to the event. Finally, doses are taken following food, and the maximum daily dose must not be exceeded.

Research evidence / Overview of Studies for Celenid

The research base describes studies conducted for various balance and inner ear-related conditions. The evidence describes controlled trials and systematic reviews conducted in patient populations selected for these symptoms. This overview summarizes the structure of the existing research without offering individual advice or interpreting results for specific outcomes.

---

Evidence Supporting Studies for Vestibular Vertigo

Research into Celenid for vestibular vertigo primarily involves controlled clinical trials designed to monitor changes in symptom intensity over defined periods. Studies used a Mean Vertigo Score (MVS) as the main outcome. The research base frequently reports on Celenid as one active component of a fixed-dose combination product; evidence for its monotherapy must be assessed alongside this context. Research provides insight into patient-reported experiences during periods of heightened symptom activity.

---

Research for Associated Symptoms and Motion Sensitivity

Celenid was evaluated in research exploring outcomes related to physical discomfort that often accompany balance disorders, specifically nausea and vomiting. Research has also explored how Celenid was studied for the prevention of motion sickness (kinetosis). Studies document the patterns observed in nausea and vomiting scores. In the context of motion sickness, research describes patterns related to its use in the context of prevention; less research examined its use after symptoms were established.

---

Clinical Evidence Landscape for Ménière's Disease

Celenid was evaluated in studies focused on patients with Ménière's disease. The clinical trials monitored patient-reported outcomes related to the frequency of vertigo attacks and the severity of tinnitus over intermediate time frames. Evidence for an effect on specific symptoms like tinnitus has been described as uncertain by some scientific reviews, and sample sizes tend to be modest.

---

Key Limitations and Remaining Uncertainties in the Research

A primary research limitation is that the results apply most directly to the specific populations studied, and the evidence quality varies across studies. The prominence of Celenid's use in a fixed combination product means comparative evidence is lacking to distinguish the precise contribution of Celenid monotherapy versus the combination. The long-term effects are not fully established, and continued research is needed to fill these knowledge gaps.

Key Studies & References

1. Pharmacological Treatment of Motion Sickness: Clinical and Regulatory Considerations

How to Store and Dispose of Celenid (Cinnarizine)

Official regulatory documents define specific requirements for storing and disposing of Celenid tablets to maintain stability and ensure safety.

Storage Requirement	Official Condition
Temperature	Store below 30 C and do not store above this temperature.
Protection	The medicine must be protected from light.
Safety	Keep the product strictly out of the sight and reach of children.
Expiration	Do not use the medicine after the end of the expiry date printed on the package.

For disposal, unused or expired Celenid must not be thrown away via wastewater or household waste. Patients are instructed to ask a pharmacist how to properly discard the medicine in accordance with local environmental regulations.